Results 121 to 129 of about 783 (129)

Safety Evaluation of Chronic Intrathecal Administration of Idursulfase-IT in Cynomolgus Monkeys

Toxicologic Pathology, 2011
Recombinant human idursulfase, an intravenous enzyme replacement therapy indicated for treatment of somatic symptoms of mucopolysaccharidosis II (Hunter syndrome), is anticipated to have minimal benefit for the cognitive impairment associated with the ...
Jing Pan, Robert B. Boyd, Mark T. Butt, Richard W. Pfeifer, Juan A. Ruiz, Teresa L. Wright, Pericles Calias, Brian R. Felice, Michael W. Heartlein   +8 more
exaly   +2 more sources

Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6years with Hunter syndrome

Molecular Genetics and Metabolism, 2015
Idursulfase beta (Hunterase®) has been used for enzyme replacement therapy (ERT) of patients with mucopolysaccharidosis II (MPS II, Hunter syndrome) aged 6 years or older since 2012 in Korea.
Young Bae Sohn, Jieun Lee, Sung Yoon Cho   +2 more
exaly   +2 more sources

Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: A perspective from the Hunter Outcome Survey (HOS)

Molecular Genetics and Metabolism, 2011
To evaluate the occurrence of infusion-related reactions (IRRs) in patients with mucopolysaccharidosis type II (MPS II) receiving idursulfase enrolled in the observational database HOS - the Hunter Outcome ...
David Whiteman
exaly   +2 more sources

A Comparison Study of Bioanalytical Methods for Characterization of Anti-Idursulfase Antibodies

Bioanalysis, 2017
Aim: Legacy methods with complex testing scheme for characterization of anti-idursulfase antibodies (ADA) were simplified and optimized in order to meet current regulatory guidance and provide more timely and cost-effective support for routine patient ...
Luying Pan
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II

Molecular Genetics and Metabolism, 2007
Joseph Muenzer, Jeffrey M Dacosta
exaly  

Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan

Expert Opinion on Drug Safety, 2020
Kazuo Ueda
exaly  

Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report

Molecular Genetics and Metabolism, 2017
Sarah Kim-Mcolash
exaly  

IgE‐mediated anaphylaxis and allergic reactions to idursulfase in patients withHunter syndrome

Allergy: European Journal of Allergy and Clinical Immunology, 2013
exaly  

Japan Elaprase® Treatment (JET) study: Idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)

Molecular Genetics and Metabolism, 2010
Yasuyuki Suzuki, Torayuki Okuyama, Gerald F Cox   +2 more
exaly